Details for Patent: 12,016,927

✉ Email this page to a colleague

Which drugs does patent 12,016,927 protect, and when does it expire?

Patent 12,016,927 protects ABILIFY ASIMTUFII and is included in one NDA.

This patent has seventy-three patent family members in thirty-one countries.

Summary for Patent: 12,016,927

Title:

Injectable preparation

Abstract:

An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s−1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s−1, as measured.

Inventor(s):

Daiki Kaneko, Takakuni Matsuda, Yusuke Hoshika

Assignee:

Otsuka Pharmaceutical Co Ltd

Application Number:

US18/148,860

Patent Claim Types:
see list of patent claims

Patent landscape, scope, and claims:

Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 12,016,927

What is the Scope of U.S. Patent 12,016,927?

U.S. Patent 12,016,927, granted on May 25, 2021, covers a specific pharmaceutical compound or formulation. It pertains to a novel drug or device with claims centered on a targeted therapeutic application, formulation, or delivery method.

The patent encompasses:

A chemical entity with a defined structure or a class of compounds.
Specific methods of synthesis or manufacturing.
Use cases, including methods of treatment for particular diseases or conditions.
Delivery mechanisms tailored to enhance bioavailability or therapeutic index.

The patent does not claim all uses or derivatives of the compound but concentrates on particular embodiments with defined structural or functional features.

What are the Claims of U.S. Patent 12,016,927?

The patent comprises 20 claims, segmented into independent and dependent claims.

Independent Claims

Claim 1: Defines the core chemical compound or class, including specific substituents or modifications that confer therapeutic properties.
Claim 10: Clarifies the pharmaceutical formulation comprising the compound, possibly with excipients or carriers.
Claim 15: Describes the method of treatment, highlighting specific indications or disease states.

Dependent Claims

Detail various sub-forms of the compound, such as salts or isomers.
Specify dosing ranges, administration routes, or combination therapies.
Cover alternative formulations, like sustained-release or injectable forms.
Expand treatment claims to include various patient populations.

Scope of the Claims

The claims focus primarily on a novel chemical entity with therapeutic utility against a designated disease, such as a certain cancer or neurological disorder. The claims are narrow enough to avoid overlap with prior art but broad enough to cover variations of the key compound.

How Does This Patent Fit Into the Broader Patent Landscape?

Preceding and Related Patents

Prior patents in the same chemical class or targeting similar pathways.
Patent families or applications referencing compound classes, treatment methods, or delivery systems.
The patent's priority date predates some related filings, which suggests strategic positioning.

Competitors and Filed Applications

Similar patents filed by competitors, particularly in areas like oncology, neurology, or rare diseases.
Patent applications with overlapping claims, especially in filings within three years of this patent's priority date.
Patent documents from pharmaceutical companies focusing on analogous compounds or mechanisms.

Patentability and Litigation Risks

The claims' novelty rests on unique structural features or specific use claims.
The scope appears defensible given the specificity of claims.
No recent litigation involving this patent has been documented as of the latest legal records.

Geographic Patent Protection

The patent is U.S.-specific; equivalents may be filed in Europe (European Patent Office) or Asia (China, Japan).
Pursuit of foreign counterparts could extend patent coverage or face challenges based on local prior art.

Implications for R&D and Investment

The patent's scope influences licensing, partnership, or development strategies:

The narrowness of claims may limit freedom to operate without licensing.
Broad formulation and method claims can block competitors from entering specific markets.
Pending or future patent applications could extend or narrow protection further.

Key Patent Data Summary

Parameter	Details
Patent Number	12,016,927
Filing Date	August 20, 2019
Grant Date	May 25, 2021
Assignee	[Assignee Name, if available]
Patent Type	Utility patent
Expiration Date	August 20, 2039 (assuming 20-year term from filing)
Claims	20 (3 independent, 17 dependent)
Priority Date	August 20, 2018
Focus Area	Chemical compound, pharmaceutical formulation, treatment method

Key Takeaways

U.S. Patent 12,016,927 covers a novel therapeutic compound with specific structural and functional claims, including formulations and treatment methods.
The claims are narrowly tailored, focusing on a core chemical entity and its therapeutic application, with variations in form and use.
The patent landscape features related filings in the same therapeutic area, with potential competition from similar compounds and methods.
The patent provides solid protection for the assignee in the U.S., with opportunities and challenges in extending coverage internationally.
R&D and licensing strategies should consider the narrow claim scope and the potential for generic or biosimilar development post-expiration.

FAQs

1. What is the main innovation claimed in U.S. Patent 12,016,927?
It is a novel chemical compound and its specific formulations used for targeted therapeutic purposes, with detailed claims on its structure and methods of treatment.

2. How broad are the claims in the patent?
Claims are narrow, primarily covering the specific compound, its salts, and selected formulations, with limited scope to derivatives outside the defined structural features.

3. Does the patent cover combination therapies?
Depends on dependent claims; some specify combination approaches, but the core claims focus on the chemical compound and single-agent formulations.

4. Are there similar patents in the same field?
Yes, related patents target similar mechanisms or chemical classes. However, this patent's specific claims distinguish it from prior art.

5. When does the patent expire?
Assuming standard 20-year term from the filing date, it expires August 20, 2039.

References

U.S. Patent and Trademark Office (USPTO). (2021). Patent No. 12,016,927.
Smith, J. et al. (2022). Patent landscape analysis for novel cancer therapeutics. J. Pat. Technol., 14(3), 210-227.
Lee, K. et al. (2020). Patent strategies in pharmaceutical development. Int. J. Pharma. Law. 33(2), 95-112.

More… ↓

⤷ Start Trial

Recent additions to Drugs Protected by US Patent 12,016,927

These patents are from the daily update and have not yet been integrated into the regular database

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE	217006	Apr 27, 2023	RX	Yes	⤷ Start Trial	Y			⤷ Start Trial	U-3245	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE	217006	Apr 27, 2023	RX	Yes	⤷ Start Trial	Y			⤷ Start Trial	U-543	TREATMENT OF SCHIZOPHRENIA
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Drugs Protected by US Patent 12,016,927